313 related articles for article (PubMed ID: 31925868)
41. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
Evoy KE; Covvey JR; Peckham AM; Ochs L; Hultgren KE
Res Social Adm Pharm; 2019 Aug; 15(8):953-958. PubMed ID: 31303196
[TBL] [Abstract][Full Text] [Related]
42. Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database.
Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
Curr Rev Clin Exp Pharmacol; 2021; 16(2):168-173. PubMed ID: 32598268
[TBL] [Abstract][Full Text] [Related]
43. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
44. Pyoderma gangrenosum-like lesions provocated by botulinum injections.
Owczarczyk-Saczonek A; Zdanowska N; Wańczyk-Dręczewska B; Wygonowska E; Placek W; Griffiths CC; Griffiths TW
Dermatol Ther; 2020 Mar; 33(2):e13227. PubMed ID: 31957116
[TBL] [Abstract][Full Text] [Related]
45. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
46. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Bonora BM; Raschi E; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
[TBL] [Abstract][Full Text] [Related]
47. Clinical manifestations and treatment outcomes of pyoderma gangrenosum following rituximab exposure: A systematic review.
Croitoru D; Nathanielsz N; Seigel K; Elsawi R; Sibbald C; Alavi A; Zipursky J; Piguet V
J Am Acad Dermatol; 2022 Sep; 87(3):655-656. PubMed ID: 34942295
[No Abstract] [Full Text] [Related]
48. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
Zink RC; Huang Q; Zhang LY; Bao WJ
Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
[TBL] [Abstract][Full Text] [Related]
49. Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis.
Aggarwal P
Ther Adv Drug Saf; 2019; 10():2042098619869077. PubMed ID: 31452867
[TBL] [Abstract][Full Text] [Related]
50. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model.
Yu Y; Ruddy KJ; Hong N; Tsuji S; Wen A; Shah ND; Jiang G
J Biomed Inform; 2019 Mar; 91():103119. PubMed ID: 30738946
[TBL] [Abstract][Full Text] [Related]
51. Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system.
Liu P; He M; Xu X; He Y; Yao W; Liu B
Seizure; 2023 Aug; 110():203-211. PubMed ID: 37423166
[TBL] [Abstract][Full Text] [Related]
52. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab.
Donmez S; Pamuk ON; Gedik M; A K R; Bulut G
Int J Rheum Dis; 2014 May; 17(4):471-5. PubMed ID: 24460826
[TBL] [Abstract][Full Text] [Related]
53. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
[TBL] [Abstract][Full Text] [Related]
54. Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.
Fan Q; Hu Y; Wang X; Zhao B
J Neurol; 2021 Jun; 268(6):2169-2174. PubMed ID: 33475824
[TBL] [Abstract][Full Text] [Related]
55. It's not always an infection: Pyoderma gangrenosum of the urogenital tract in two patients with multiple sclerosis treated with rituximab.
Parrotta E; Kopinsky H; Abate J; Ryerson LZ; Krupp LB
Mult Scler Relat Disord; 2023 Feb; 70():104483. PubMed ID: 36580875
[TBL] [Abstract][Full Text] [Related]
56. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
Nishtala PS; Gill S; Chyou TY
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1689-1695. PubMed ID: 33078448
[TBL] [Abstract][Full Text] [Related]
57. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
[No Abstract] [Full Text] [Related]
58. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
[No Abstract] [Full Text] [Related]
59. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
[TBL] [Abstract][Full Text] [Related]
60. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS).
Stamoula E; Stamatellos VP; Vavilis T; Dardalas I; Papazisis G
Expert Opin Drug Saf; 2024 Feb; 23(2):239-245. PubMed ID: 37589503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
